SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor's stock is trending following the announcement of a special dividend distribution of warrants, designed to align shareholder value with management performance, sparking mixed reactions within the investment community. While some view the warrants as a bullish signal, indicating confidence in the company's future, others express concerns about recent earnings, debt levels, and the overall state of the housing market, leading to volatile trading and a debate about the company's long-term viability.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI (SOUN) is trending as investors discuss its Q3 earnings and raised FY25 revenue outlook, with some expressing concern over the market's reaction to AI stocks. Despite positive sentiment around the company's growth and cash position, the community debates whether broader market conditions will impact its performance. Bullish investors are anticipating a potential short squeeze and a rise in price, while others remain cautious due to market volatility.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending amid news of an exclusive ESPN partnership, with community debate focused on whether this deal will boost the stock despite a broader market downturn and investor concerns about profitability. A $2 billion share buyback announcement has further fueled discussions, with some questioning the company's financial capacity while others see it as a bullish signal. Technical analysis suggests a potential turning point, as bulls eye the ESPN pipeline while bears cite dilution and competition concerns.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation ($ACHR) is trending as discussions revolve around the company's acquisition of Hawthorne Airport and a potential partnership with Tesla, although concrete evidence of the latter is debated within the community. Some investors express concerns about dilution and cash burn, while others view the airport acquisition as a strategic move for future air taxi operations and AI development. Bullish sentiment remains due to potential catalysts like upcoming earnings and the Dubai Air Show.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending due to a significant earnings beat, with discussions focused on the company's impressive revenue growth and future AI cloud potential. The community is buzzing about potential catalysts, including a possible partnership with NVDA and the impact of a large Microsoft contract. Community members are also discussing a possible short squeeze.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is buzzing as shareholders cast their votes on Elon Musk's proposed compensation package, sparking debates around dilution and whether Musk's leadership justifies the payout. Community sentiment is split, with some seeing it as a catalyst for growth and others as a potential burden on the company's future, all while the stock navigates a volatile market.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Recent news of a CRO change, bringing in a former Google VP, is sparking mixed reactions and driving active discussion around the company's future direction. While some view this as a positive move, others express concerns about the timing and potential implications for upcoming earnings. Community sentiment appears divided as investors weigh the potential impact on TTD's competitive position within the broader ad tech landscape.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors discuss its Q3 earnings, which beat revenue expectations but missed on EPS, and potential government partnerships to boost growth. Community members are weighing the impact of reported earnings against the backdrop of the US onshoring initiative for critical minerals and rare earth elements, and some anticipate a surge in the stock price following the earnings call. Broader discussions encompass the rare earth and critical metals sector, including potential effects from deals with China, and long-term growth prospects.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UNH is trending downwards, with the community pointing to a potential Warren Buffett sell-off and DOJ investigations as possible catalysts; some traders speculate on a healthcare spending deal potentially driving a future rebound. The stock's recent decline, despite strong earnings, has frustrated investors who are questioning leadership and possible leaked bad news, while others are seeing the dip as a buying opportunity for a long-term winner.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending following positive earnings reports and the launch of Innodata Federal, a new business unit focused on AI innovation across the U.S. government, sparking excitement for potential major revenue catalysts. Community members are actively discussing new leadership appointments, potential government contracts, and the overall growth prospects of this core AI company, with some speculating about future partnerships and a potential move towards sovereign AI capabilities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity

<ul class="summary-bullets"><li>Eli Lilly led a Stocktwits poll, with 32% support, ahead of Novo Nordisk, Hims &amp; Hers Health and Viking Therapeutics at 16%.</li><li>Lilly and Novo advanced oral obesity drugs while nearing TrumpRx pricing deals to expand Medicare access for Zepbound and Wegovy.</li><li>Hims &amp; Hers pursued GLP-1 partnerships, and Viking gained attention for its dual GLP-1/GIP drug VK2735, described by Jefferies as “class-leading.”</li></ul>Eli Lilly topped a Stocktwits poll asking retail traders which obesity-drug stock they are most bullish on over the next five years, outpacing rival Novo Nordisk as investors weigh fresh policy developments and the next wave of obesity treatments.The survey of about 3,300 participants showed 32% of votes in favour of Eli Lilly, followed by Novo Nordisk and Hims &amp; Hers Health, tied at 26%, and Viking Therapeutics at 16%. The results come as the world’s biggest drugmakers prepare to expand access to their obesity therapies under an expected U.S. pricing plan, while smaller firms position for partnerships and new launches.<h2 class="st-heading-2">Lilly Leads With New Therapies And Policy Tailwinds</h2>Eli Lilly remains the frontrunner in the fast-growing obesity-drug market, driven by strong demand for its injectable therapies Zepbound and Mounjaro, both of which are based on the active ingredient tirzepatide. Zepbound is approved for adults with obesity or overweight and associated conditions.Eli Lilly’s Mounjaro and Zepbound sales beat market expectations in the third quarter (Q3), raking in over $10 billion combined, while Novo Nordisk’s Wegovy came in below estimates and Ozempic slightly exceeded forecasts&nbsp;(both generating close to $8 billion in sales),&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/10/30/eli-lilly-lly-earnings-q3-2025.html#:~:text=Mounjaro%20raked%20in%20%246.52%20billion,revenue%20for%20the%20third%20quarter.">CNBC</a>&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/11/05/wegovy-ozempic-maker-novo-nordisk-q3-earnings.html">reported</a>.The company has also completed Phase 3 trials for Orforglipron, a once-daily oral GLP-1 treatment that Lilly said met key regulatory criteria for a priority review submission this quarter. UBS analysts said the oral pill could widen Lilly’s reach in markets where injectable therapies face storage or cost barriers.In parallel, Lilly and Novo Nordisk are in talks with the U.S. administration under the “TrumpRx” initiative to lower the price of obesity drugs to about $149 per month in exchange for expanded Medicare coverage. The plan would represent the third major pricing agreement between the government and large pharmaceutical firms since September.<h2 class="st-heading-2">Novo Nordisk Ramps Up Obesity Pipeline Amid Profit Pressure</h2>Novo Nordisk, the maker of Wegovy and Ozempic, continues to expand its obesity-drug franchise but faces slowing sales growth and pricing challenges. The company lowered its full-year profit and sales forecasts, citing intensifying competition and weaker momentum in GLP-1 revenue.At the ObesityWeek 2025 conference, Novo presented late-stage data for its oral semaglutide 25 mg formulation, demonstrating significant weight loss and cardiovascular benefits comparable to those of its injectable product, Wegovy.&nbsp;Novo and Lilly are also in advanced discussions with the U.S. government to include their drugs in the TrumpRx pricing plan. Under the proposal, both companies would offer entry-level doses of Wegovy and Zepbound at about $149 per month for Medicare patients, potentially broadening access but reducing global pricing leverage.<h2 class="st-heading-2">Hims &amp; Hers Expands Access Model With GLP-1 Partnerships</h2>Digital health company Hims &amp; Hers Health has quickly become one of the most-watched newcomers in the obesity drug sector. The company, which offers telehealth-based access to GLP-1 weight-loss medications, said it is in discussions with Novo Nordisk to distribute Wegovy injections and an eventual oral version through its platform once regulatory approval is secured.Hims &amp; Hers expects to generate about $725 million in annual revenue from its weight-loss business in 2026, supported by new fulfillment and compounding facilities to meet growing demand. The firm’s total subscriber base has risen to nearly 2.5 million, and it continues to expand its range of prescription offerings tied to metabolic and wellness care.<h2 class="st-heading-2">Viking Therapeutics Advances Dual-Action Obesity Drug</h2>Viking is advancing VK2735, a dual GLP-1/GIP agonist being developed in both injectable and oral forms. The company recently began a maintenance dosing trial under its Vanquish program, evaluating weekly and monthly regimens in adults with obesity.Phase 2 results showed weight loss of up to 15%, with Jefferies describing the data as “class-leading” in the oral drug category. Viking said it plans to meet with the U.S. Food and Drug Administration later this year to discuss late-stage trial design and expects to file a new drug application for its next obesity candidate targeting the amylin receptor in 2026.<h2 class="st-heading-2">Stocktwits Traders Stay Bullish On GLP-1 Leaders</h2>On Stocktwits, retail sentiment was ‘extremely bullish’ for Eli Lilly, Novo Nordisk, and Hims &amp; Hers Health amid ‘high’ to ‘extremely high’ message volume, while sentiment for Viking Therapeutics was ‘bullish’ amid ‘high’ message volume.So far this year, Eli Lilly is up 21%, Hims &amp; Hers Health has gained 81%, while Novo Nordisk is down 43% and Viking Therapeutics has slipped 9%.A Stocktwits user said Viking’s new VK-2735 data showed rapid, dose-dependent weight loss and metabolic improvements, suggesting the dual GLP-1/GIP drug could avoid the nausea issues seen with Lilly and Novo. The user called it a “tolerability unlock” and said the upcoming Vanquish-1 trial could set up a true head-to-head test with market leaders.<stembedurl>https://stocktwits.com/LastResort/message/635054466</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The entrance to the Eli Lilly factory in Kinsale, Co Cork, where weight loss drug Mounjaro is made. Picture date: Sunday May 18, 2025.

Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years?

Eli Lilly led a Stocktwits poll, with 32% support, ahead of Novo Nordisk, Hims & Hers Health and Viking Therapeutics at 16%.

Equity

Lightning Round: I lack a catalyst to recommend Zoom, says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stocks including: Viking Therapeutics, Altria, Zoom, and ProFrac Holdings...

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics to Participate at Upcoming Investor Conferences Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, Nov. 4, 2025 SAN DIEGO, Nov. 4, 2025...

Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?

NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.

<ul class="summary-bullets"><li>VKTX shares&nbsp;have surged&nbsp;about 45% in October,&nbsp;set for their strongest monthly gain of 2025.</li><li>Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.</li><li>Pfizer’s stalled Metsera deal and past struggles with its own obesity program added to speculation that Viking could become a future acquisition target.</li></ul>Viking Therapeutics shares have climbed nearly 45%&nbsp;in October, putting the stock on track for its best monthly performance of 2025, as investor excitement builds over its experimental obesity treatment and renewed analyst optimism.<h2 class="st-heading-2">Canaccord Starts Coverage With ‘Buy’&nbsp;</h2>Viking&nbsp;shares have rallied&nbsp;amid a slew of bullish analyst calls on Wall Street following quarterly earnings, with&nbsp;the latest coming from Canaccord Genuity’s initiation on Wednesday with a ‘Buy’ rating and $106 price target, representing an upside of 178% from the stock’s last close. The brokerage firm said Viking stands out as a leader in the obesity drug development space, citing its strong Phase 2 efficacy data from August for the oral version of VK2735.Canaccord expects readouts from Viking’s two Phase 3 trials in 2027 and mid-2028, and believes VK2735 can differentiate on multiple fronts in a crowded obesity drug pipeline.<h2 class="st-heading-2">Pfizer And Novo Nordisk Fuel M&amp;A Speculation</h2><a href="https://stocktwits.com/news-articles/markets/equity/retail-investors-expect-viking-therapeutics-to-bag-deal/cLGFym0R3xj">Investor chatter also intensified</a> after Novo Nordisk submitted an unsolicited proposal to acquire Metsera, a company that Pfizer had already agreed to purchase in September.Metsera has given Pfizer four business days to adjust its offer, fueling speculation among traders on Stocktwits that Pfizer might turn its attention to Viking if its Metsera deal falls through. Pfizer discontinued its own oral weight-loss candidate, Danuglipron, in April 2025, following safety issues, and has been seeking other ways to re-enter the obesity market.<h2 class="st-heading-2">Viking’s Obesity Drug Program</h2>Viking is developing VK2735, a dual agonist of the GLP-1 and GIP receptors, both of which play key roles in regulating glucose, appetite, and body weight. The company is testing subcutaneous and oral versions of the therapy in clinical trials.Early-stage data have shown positive safety and efficacy signals, reinforcing Wall Street’s belief that Viking could become a meaningful player in the weight-loss drug race dominated by Novo Nordisk and Eli Lilly.<h2 class="st-heading-2">Q3 Earnings And Outlook</h2>Viking Therapeutics reported a net loss of $52.3 million for the third quarter, in line with expectations, as it continues to invest heavily in its obesity and metabolic disease pipeline. Viking said it plans to meet with the U.S. Food and Drug Administration (FDA) by year-end to discuss advancing the oral formulation into late-stage clinical trials.The company noted that Phase III enrollment for its injectable version of VK2735 remains ahead of schedule, with completion expected in early 2026. A maintenance dosing study is currently underway to assess how best to sustain weight loss over time.&nbsp;Viking also plans to file an Investigational New Drug (IND) application with the FDA in the first quarter of 2026 for its next program targeting the amylin receptor, a mechanism that could complement GLP-1 and GIP therapies by improving appetite control and weight regulation.<h2 class="st-heading-2">Stocktwits Users See Viking At Center Of Pfizer–Novo Rivalry&nbsp;</h2>On Stocktwits, retail sentiment for Viking was ‘extremely bullish’ amid a 200% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:969/139;" src="https://news.stocktwits-cdn.com/vktx_ss_jpg_85eeea1fb9.webp" alt="vktx ss.jpg" width="969" height="139"><figcaption>VKTX sentiment and message volume as of October 31 | Source: Stocktwits</figcaption></figure>Some traders speculated that Novo Nordisk’s renewed bid for Metsera may be tied to competitive pressure from Viking’s obesity program. One bullish user&nbsp;<a href="https://stocktwits.com/biolover/message/634429740">suggested</a> Novo’s main interest in Metsera is its early-stage oral GLP-1/GIP agonist, adding that Novo knows Viking’s oral 2735 could be a long-term threat.<stembedurl>https://stocktwits.com/biolover/message/634429740</stembedurl>Another trader&nbsp;<a href="https://stocktwits.com/Bagholding_VKTX/message/634425707">agreed</a>,&nbsp;speculating Novo may have approached Viking before turning to Metsera, but “panicked” once Pfizer entered the picture. The user added that institutional investors may share the same view, noting Viking’s strong price reaction.<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/634425707</stembedurl><a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

<ul class="summary-bullets"><li>Novo Nordisk announced on Thursday that it has submitted an unsolicited proposal to acquire Metsera, following Pfizer's agreement to acquire the smaller obesity biopharmaceutical company in September.</li><li>Pfizer was previously developing its own oral weight-loss drug, Danuglipron, but discontinued its development in April 2025 due to liver enzyme elevations in patients.</li><li>The company is now looking to enter the booming obesity market with an acquisition. &nbsp;</li></ul>Retail investors on Stocktwits expect Pfizer to make an acquisition bid for Metsera’s rival, Viking Therapeutics, as the company’s agreed-upon deal with Metsera hangs in limbo.Danish drugmaker Novo Nordisk (NVO) <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-submits-revised-bid-for-metsera-enters-bidding-war-with-pfizer/cLGFsgdR3x2">announced</a> on Thursday that it has submitted an unsolicited proposal to acquire Metsera, Inc. (MTSR), following Pfizer's (PFE) agreement to acquire the smaller obesity biopharmaceutical company in September. Metsera has now given Pfizer four business days to negotiate potential adjustments to the existing transaction. The company also noted it would be entitled to terminate the Pfizer merger agreement if Novo’s proposal continues to constitute a superior proposal.&nbsp;“The best part would be if PFE lets NVO walk away with MTSR rather than up its own bid a few billion dollars, and instead makes a better offer to VKTX,” a Stocktwits user wrote.<stembedurl>https://stocktwits.com/spodero/message/634314721</stembedurl>Another sees Viking ending up with a good deal in time.<stembedurl>https://stocktwits.com/Idvst8/message/634311871</stembedurl>Shares of VKTX traded 10% higher at the time of writing. On Stocktwits, retail sentiment around VKTX stayed within the ‘bullish’ territory while message volume remained at ‘high’ levels.Pfizer was previously developing its own oral weight-loss drug, Danuglipron, but discontinued its development in April 2025 due to liver enzyme elevations in patients. The company is now looking to enter the booming obesity market with an acquisition.<h2 class="st-heading-2">Viking’s Obesity Program</h2>Viking, meanwhile, is evaluating both subcutaneous and oral formulations of its obesity program VK2735 in clinical trials. It is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both.In early and mid-stage trials, subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> is down 4% this year and approximately 46% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-cybertrucks-for-second-time-in-october-this-time-for-faulty-light-bar/cLGFud9R3xe">Tesla Recalls Cybertrucks For Second Time In October – This Time For A Faulty Light Bar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera 

Viking and Metsera are both attempting to develop drugs for the treatment of obesity.

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2025

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2025 Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in...

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil

VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

$LLY

$NVO

$VKTX

$HIMS

Which obesity-drug stock are you most bullish on over the next 5 years?

Current Price	$37.39
Prev Close	$36.47
Open	$36.02
Dividend Yield	0.00%
50-Day Moving Average	$29.90
Beta	1.33
Avg. Volume	4.86M
PE Ratio	-17.22

52-Week High	$70.41
52-Week Low	$18.92
Market Capitalization	$4.12B
EPS (Annual)	-$1.01
Price to Book	5.75
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VKTX News

VKTXViking Therapeutics Inc